VHH antibodies, also known as nanobodies, are single-domain antibodies that are derived from camelid heavy-chain antibodies. Due to their small size (~ 15 kDa) and diverse applications in bio-derived therapeutics, these antibodies have widespread attention in the research and development community, with some examples below from just this week!
VHH antibodies offer stability, small size, and strong binding. Biointron highlights their promise in diagnostics, therapeutics, and next-generation antibody design.
Antibodies defend health by neutralizing pathogens, aiding phagocytosis, and activating complement. Biointron explains these vital functions in immunity and therapy.
Antibody-drug conjugates unite precision with potency. Biointron outlines how ADCs combine antibodies with cytotoxic drugs to deliver targeted cancer therapies.
Learn about Fab, F(ab')2, and Fc antibody fragments—how they are generated, their roles in antigen targeting, and their evolving applications in biomedical research and therapy.
Single-chain variable fragments (scFvs) combine small size with strong binding. Biointron highlights their history, uses in diagnostics and therapy, and production expertise.
You can also contact us on the Scientist and Science Exchange marketplaces.